Stock 688177 BIO-THERA SOLUTIONS, LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Bio-Thera Solutions, Ltd.

Equities

688177

CNE100003R98

Biotechnology & Medical Research

End-of-day quote Shanghai S.E.
Other stock markets
 23:00:00 12/05/2024 BST 		5-day change 1st Jan Change
30.9 CNY -6.08% Intraday chart for Bio-Thera Solutions, Ltd. -6.70% -25.07%
05-10 China Grants Clinical Trial Approval to Bio-Thera's Anti-Tumor Combination Therapy MT
04-29 Bio-Thera Solutions, Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Valuation

Fiscal Period: December 2023 2024 2025 2026
Capitalization 1 17,077 12,795 - -
Enterprise Value (EV) 1 17,077 12,795 12,795 12,795
P/E ratio -42.5 x -618 x 22.4 x 9.63 x
Yield - - - -
Capitalization / Revenue - 8.59 x 5.15 x 2.9 x
EV / Revenue - 8.59 x 5.15 x 2.9 x
EV / EBITDA - 59.8 x 15.9 x 7 x
EV / FCF - 60.2 x 26 x 7.77 x
FCF Yield - 1.66% 3.85% 12.9%
Price to Book - 9.54 x 6.52 x 3.72 x
Nbr of stocks (in thousands) 414,080 414,080 - -
Reference price 2 41.24 30.90 30.90 30.90
Announcement Date 23/02/24 - - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2023 2024 2025 2026
Net sales 1 0.7 - 1,490 2,484 4,415
EBITDA 1 -969.4 - 214 803.5 1,828
EBIT 1 -1,024 - 142.5 717 1,739
Operating Margin -146,269.71% - 9.56% 28.87% 39.39%
Earnings before Tax (EBT) 1 -1,023 - -22 672 1,564
Net income 1 -1,023 -401.3 -22 571 1,329
Net margin -146,088.83% - -1.48% 22.99% 30.1%
EPS 2 - -0.9700 -0.0500 1.380 3.210
Free Cash Flow 1 - - 212.6 492.4 1,646
FCF margin - - 14.27% 19.83% 37.28%
FCF Conversion (EBITDA) - - 99.32% 61.29% 90.04%
FCF Conversion (Net income) - - - 86.24% 123.85%
Dividend per Share - - - - -
Announcement Date 27/02/20 23/02/24 - - -
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2023 2024 2025 2026
Net Debt - - - - -
Net Cash position - - - - -
Leverage (Debt/EBITDA) - - - - -
Free Cash Flow 1 - - 213 492 1,646
ROE (net income / shareholders' equity) - - 8.3% 31.8% 42.9%
ROA (Net income/ Total Assets) - - 5.25% 18.3% 29.1%
Assets 1 - - -419 3,120 4,567
Book Value Per Share 2 1.780 - 3.240 4.740 8.300
Cash Flow per Share 2 -1.690 - -0.9300 1.460 2.420
Capex 1 - - 116 128 156
Capex / Sales - - 7.75% 5.15% 3.52%
Announcement Date 27/02/20 23/02/24 - - -
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
30.9 CNY
Average target price
54 CNY
Spread / Average Target
+74.76%
Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
BIO-THERA SOLUTIONS, LTD. Stock Bio-Thera Solutions, Ltd.
-25.07% 1.89B
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+5.66% 109B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+11.23% 105B
ARGENX SE Stock argenx SE
-0.38% 22.25B
BIONTECH SE Stock BioNTech SE
-12.15% 22.09B
GENMAB A/S Stock Genmab A/S
-7.66% 18.68B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-36.52% 17.58B
BEIGENE, LTD. Stock BeiGene, Ltd.
-10.09% 16.85B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.33% 13.76B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+36.58% 12.46B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. 688177 Stock
  4. Financials Bio-Thera Solutions, Ltd.